Covered recipient · General Payments record
MOSHE YAIR LEVY
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$571,890.01
512 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $447,244.25 | 124 |
| Consulting Fee | $57,925.09 | 26 |
| Travel and Lodging | $53,946.74 | 199 |
| Food and Beverage | $8,903.93 | 161 |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,000.00 | 1 |
| Honoraria | $870.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 6 of 11; records 251–300 of 512 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MOSHE YAIR LEVY
NPI 1518059807 · CMS profile ID 833077
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
DALLAS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 11; records 251–300 of 512 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518059807?year=2024&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MOSHE YAIR LEVY, NPI 1518059807, CMS profile ID 833077. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 11; records 251–300 of 512 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518059807?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MOSHE YAIR LEVY, NPI 1518059807, CMS profile ID 833077. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 11; records 251–300 of 512 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518059807?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MOSHE YAIR LEVY, NPI 1518059807, CMS profile ID 833077, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 11; records 251–300 of 512 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1518059807?year=2024&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
512 matching records · $571,890.01 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–300 of 512.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $6,987.00 | 06/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101752820 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5.00 | 06/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101752809 | CMS |
| E.R. Squibb & Sons, L.L.C. | $101.43 | 06/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101752813 | CMS |
| E.R. Squibb & Sons, L.L.C. | $26.72 | 06/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101752828 | CMS |
| E.R. Squibb & Sons, L.L.C. | $33.50 | 06/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101752831 | CMS |
| GlaxoSmithKline, LLC. | $4,800.00 | 06/14/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116169419 | CMS |
| GENZYME CORPORATION | $2,716.00 | 06/12/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139704167 | CMS |
| Ipsen Biopharmaceuticals, Inc | $2,610.00 | 06/12/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091954817 | CMS |
| GlaxoSmithKline, LLC. | $4,800.00 | 06/10/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116660915 | CMS |
| BeiGene USA, Inc. | $1,875.00 | 06/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120845432 | CMS |
| Regeneron Pharmaceuticals, Inc. | $415.50 | 06/07/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114401903 | CMS |
| Regeneron Pharmaceuticals, Inc. | $3,324.00 | 06/07/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114401905 | CMS |
| Regeneron Pharmaceuticals, Inc. | $3,324.00 | 06/07/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114401907 | CMS |
| Regeneron Pharmaceuticals, Inc. | $30.00 | 06/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114401909 | CMS |
| Regeneron Pharmaceuticals, Inc. | $12.06 | 06/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114401911 | CMS |
| Regeneron Pharmaceuticals, Inc. | $12.06 | 06/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114401913 | CMS |
| SOBI, INC | $1,155.00 | 06/06/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141435209 | CMS |
| E.R. Squibb & Sons, L.L.C. | $935.20 | 06/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101752845 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,500.59 | 06/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101752856 | CMS |
| GlaxoSmithKline, LLC. | $15.53 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116220138 | CMS |
| Celgene Corporation | $300.00 | 06/04/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101181968 | CMS |
| E.R. Squibb & Sons, L.L.C. | $242.74 | 06/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101752817 | CMS |
| E.R. Squibb & Sons, L.L.C. | $132.61 | 06/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101752824 | CMS |
| ABBVIE INC. | $2,250.00 | 06/03/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103160688 | CMS |
| GlaxoSmithKline, LLC. | $16.38 | 06/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116070372 | CMS |
| Eli Lilly and Company | $132.26 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135223191 | CMS |
| PFIZER INC. | $25.80 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131695706 | CMS |
| GlaxoSmithKline, LLC. | $124.35 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116427322 | CMS |
| Kite Pharma, Inc. | $4,800.00 | 05/30/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128613395 | CMS |
| Mirati Therapeutics, Inc. | $21.01 | 05/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117176326 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,350.00 | 05/28/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105862822 | CMS |
| BeiGene USA, Inc. | $1,875.00 | 05/28/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120845436 | CMS |
| Merck Sharp & Dohme LLC | $27.09 | 05/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141836930 | CMS |
| GlaxoSmithKline, LLC. | $841.08 | 05/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116584105 | CMS |
| GENZYME CORPORATION | $38.47 | 05/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139704041 | CMS |
| Lilly USA, LLC | $1,800.00 | 05/20/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135224788 | CMS |
| Kite Pharma, Inc. | $24.18 | 05/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128613397 | CMS |
| Kite Pharma, Inc. | $7.77 | 05/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128613399 | CMS |
| Kite Pharma, Inc. | $48.38 | 05/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128613401 | CMS |
| Kite Pharma, Inc. | $12.00 | 05/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128613403 | CMS |
| Kite Pharma, Inc. | $33.50 | 05/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128613405 | CMS |
| PFIZER INC. | $84.50 | 05/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131329578 | CMS |
| GENZYME CORPORATION | $22.04 | 05/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139704069 | CMS |
| Genmab U.S., Inc. | $2,250.00 | 05/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126830036 | CMS |
| GlaxoSmithKline, LLC. | $762.10 | 05/16/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116490538 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,750.00 | 05/14/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105462701 | CMS |
| Incyte Corporation | $1,845.00 | 05/13/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141212065 | CMS |
| SOBI, INC | $23.41 | 05/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141408698 | CMS |
| AstraZeneca Pharmaceuticals LP | $36.19 | 05/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105293401 | CMS |
| AstraZeneca Pharmaceuticals LP | $116.15 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105807964 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $18,374.31 | 4 |
| PY2025 | Principal investigator | $1,783,451.43 | 309 |
| PY2024 | Recipient | $14,342.01 | 4 |
| PY2024 | Principal investigator | $2,650,190.68 | 219 |
| PY2023 | Recipient | $45,945.53 | 12 |
| PY2023 | Principal investigator | $3,151,244.91 | 146 |
| PY2022 | Recipient | $24,207.49 | 10 |
| PY2022 | Principal investigator | $2,688,028.66 | 118 |
| PY2021 | Recipient | $6,310.00 | 9 |
| PY2021 | Principal investigator | $2,785,098.97 | 123 |
| PY2020 | Recipient | $1,270.00 | 2 |
| PY2020 | Principal investigator | $1,044,960.64 | 164 |
| PY2019 | Recipient | $11,711.46 | 7 |
| PY2019 | Principal investigator | $481,395.12 | 95 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
313 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 12/31/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY SOUTHWEST FORT WORTH | A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies | No dispute reported | 06/30/2026 | 1202532524 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 12/29/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY-BAYLOR SAMMONS CANCER CENTER | A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1240599860 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $434,274.00 | 12/18/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER | An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment | No dispute reported | 06/30/2026 | 1190313979 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211677043 |
| Recipient | Acrotech Biopharma Inc. | $15,750.00 | 12/11/2025 | Covered Recipient Physician | SPI-BEL-301 | No dispute reported | 06/30/2026 | 1237537867 |
| Principal investigator 1 | ABBVIE INC. | $2,051.40 | 12/08/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202529662 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,075.04 | 12/04/2025 | Non-covered Recipient Entity BAYLOR RESEARCH INSTITUTE | A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) | No dispute reported | 06/30/2026 | 1190300195 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $455.00 | 12/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665142 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $813.00 | 12/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665190 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $455.00 | 12/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665274 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $500.00 | 12/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665298 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,500.00 | 12/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665300 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 12/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665310 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,250.00 | 12/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665392 |
| Principal investigator 1 | BeOne Medicines Ltd. | $259.00 | 11/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190329529 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,825.00 | 11/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190329533 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,058.00 | 11/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335364 |
| Principal investigator 1 | BeOne Medicines Ltd. | $10,334.00 | 11/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335373 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 11/26/2025 | Non-covered Recipient Entity Baylor Rsrch Inst Irb | A Study of Daratumumab | No dispute reported | 06/30/2026 | 1175278278 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,004.80 | 11/26/2025 | Non-covered Recipient Entity Baylor Rsrch Inst Irb | A Study of Daratumumab | No dispute reported | 06/30/2026 | 1175279628 |
| Principal investigator 1 | Janssen Research & Development, LLC | $369.85 | 11/26/2025 | Non-covered Recipient Entity Baylor Rsrch Inst Irb | A Study of Daratumumab | No dispute reported | 06/30/2026 | 1175280809 |
| Principal investigator 1 | ABBVIE INC. | $4,557.80 | 11/25/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202525384 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 11/18/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211677009 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 11/13/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202524233 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 11/13/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202524235 |
| Principal investigator 1 | ABBVIE INC. | $1,250.00 | 11/13/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202524237 |
| Principal investigator 1 | ABBVIE INC. | $1,506.70 | 11/12/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202523919 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,000.00 | 11/12/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190329531 |
| Principal investigator 1 | BeOne Medicines Ltd. | $59.00 | 11/12/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190329537 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,804.00 | 11/12/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190334167 |
| Principal investigator 1 | BeOne Medicines Ltd. | $198.00 | 11/12/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335389 |
| Principal investigator 1 | BeOne Medicines Ltd. | $29.00 | 11/12/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335398 |
| Principal investigator 1 | BeOne Medicines Ltd. | $198.00 | 11/12/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335432 |
| Principal investigator 1 | BeOne Medicines Ltd. | $408.00 | 11/12/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335436 |
| Principal investigator 1 | BeOne Medicines Ltd. | $414.00 | 11/12/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335452 |
| Principal investigator 1 | BeOne Medicines Ltd. | $198.00 | 11/12/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335457 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,000.00 | 11/12/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335466 |
| Principal investigator 1 | Epizyme, Inc. | $1,125.00 | 11/10/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281672 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665144 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665160 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665188 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665206 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665208 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665214 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665236 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665260 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665262 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665290 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665332 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665360 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665362 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665366 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665376 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665398 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665414 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665428 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665430 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665432 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $30.00 | 11/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665438 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,234.00 | 11/04/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335423 |
| Principal investigator 1 | BeOne Medicines Ltd. | $408.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190329535 |
| Principal investigator 1 | BeOne Medicines Ltd. | $822.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190329539 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,058.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335359 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,628.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335378 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,234.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335394 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,058.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335411 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,234.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335415 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,825.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335428 |
| Principal investigator 1 | BeOne Medicines Ltd. | $5,470.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335444 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,825.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335448 |
| Principal investigator 1 | BeOne Medicines Ltd. | $408.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335461 |
| Principal investigator 1 | BeOne Medicines Ltd. | $408.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335471 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 10/27/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676947 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 10/22/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202518175 |
| Principal investigator 1 | ABBVIE INC. | $29,291.60 | 10/16/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202517377 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,000.00 | 10/07/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335369 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,000.00 | 10/07/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335384 |
| Principal investigator 1 | BeOne Medicines Ltd. | $408.00 | 10/07/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335403 |
| Principal investigator 1 | BeOne Medicines Ltd. | $408.00 | 10/07/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335407 |
| Principal investigator 1 | BeOne Medicines Ltd. | $499.00 | 10/07/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335419 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,000.00 | 10/07/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335440 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $130,282.20 | 10/06/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER | A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | No dispute reported | 06/30/2026 | 1190307761 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $813.00 | 10/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665156 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 10/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665292 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $549.00 | 10/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665350 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 10/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665388 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,283.00 | 10/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665472 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $38,471.62 | 10/01/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190301351 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 09/30/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202512898 |
| Principal investigator 1 | BeOne Medicines Ltd. | $52,400.00 | 09/29/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190336710 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 09/19/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676902 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 09/19/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676910 |
| Principal investigator 1 | Epizyme, Inc. | $1,125.00 | 09/17/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281426 |
| Recipient | ABBVIE INC. | $1,875.00 | 09/10/2025 | Covered Recipient Physician | A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202399641 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,001.14 | 09/09/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER | A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | No dispute reported | 06/30/2026 | 1190311955 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $473.64 | 09/09/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER | A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment | No dispute reported | 06/30/2026 | 1190311959 |
| Principal investigator 1 | ABBVIE INC. | $5,675.54 | 09/04/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202509708 |
| Principal investigator 1 | ABBVIE INC. | $10,393.50 | 09/04/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202509710 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,276.00 | 09/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665226 |
| Principal investigator 1 | BeOne Medicines Ltd. | $5,122.00 | 09/02/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190334171 |
| Principal investigator 1 | Janssen Research & Development, LLC | $163.00 | 08/18/2025 | Non-covered Recipient Entity Baylor Rsrch Inst Irb | A Study of Daratumumab | No dispute reported | 06/30/2026 | 1175280027 |
| Principal investigator 1 | ABBVIE INC. | $266.50 | 08/06/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202502450 |
| Recipient | Novartis Pharmaceuticals Corporation | $263.17 | 08/05/2025 | Covered Recipient Physician | CABL001AUS08 | No dispute reported | 06/30/2026 | 1190293178 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665140 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,079.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665150 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,982.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665154 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665172 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $96.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665174 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,276.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665176 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,283.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665186 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665222 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,359.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665228 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,276.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665238 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $96.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665244 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $190.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665264 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $96.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665270 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665286 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,359.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665330 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665354 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $813.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665400 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665410 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $190.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665458 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,359.00 | 08/04/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665480 |
| Principal investigator 1 | Genentech, Inc. | $6,340.00 | 07/29/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676816 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,881.51 | 07/28/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190311949 |
| Principal investigator 1 | ABBVIE INC. | $4,875.00 | 07/24/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202499474 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 07/24/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676804 |
| Principal investigator 1 | Acerta Pharma LLC | $13,346.00 | 07/09/2025 | Non-covered Recipient Entity BAYLOR SCOTT AND WHITE RESEARCH INSTITUTE | Part 1 FL An Open label Phase 1b Study of ACP196 Alone or in Combination with Rituximab in Subjects with Follicular Lymphoma Part 2 MZL An Open label Phase 1b or 2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent Bcell Non Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1185555752 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $455.00 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665194 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,079.00 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665278 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,359.00 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665304 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665306 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665336 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,515.50 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665352 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665374 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665380 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $455.00 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665390 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665416 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,359.00 | 07/03/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665482 |
| Principal investigator 1 | ABBVIE INC. | $6,194.00 | 07/02/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202493983 |
| Principal investigator 1 | BeOne Medicines Ltd. | $198.00 | 06/17/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190326856 |
| Principal investigator 1 | BeOne Medicines Ltd. | $198.00 | 06/17/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190326862 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,000.00 | 06/17/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190326866 |
| Principal investigator 1 | Acerta Pharma LLC | $156.00 | 06/16/2025 | Non-covered Recipient Entity BAYLOR RESEARCH INST | Part 1 FL An Open label Phase 1b Study of ACP196 Alone or in Combination with Rituximab in Subjects with Follicular Lymphoma Part 2 MZL An Open label Phase 1b or 2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent Bcell Non Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1185555748 |
| Principal investigator 1 | BeOne Medicines Ltd. | $32.00 | 06/10/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190326852 |
| Principal investigator 1 | BeOne Medicines Ltd. | $29.00 | 06/10/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190326854 |
| Principal investigator 1 | BeOne Medicines Ltd. | $198.00 | 06/10/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190326858 |
| Principal investigator 1 | BeOne Medicines Ltd. | $59.00 | 06/02/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190326860 |
| Principal investigator 1 | BeOne Medicines Ltd. | $198.00 | 06/02/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190326864 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 06/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665280 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 06/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665282 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 06/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665294 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 06/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665314 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 06/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665328 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 06/02/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665346 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,804.00 | 05/30/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190331019 |
| Principal investigator 1 | Epizyme, Inc. | $2,145.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281218 |
| Principal investigator 1 | Epizyme, Inc. | $2,130.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281228 |
| Principal investigator 1 | Epizyme, Inc. | $2,213.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281238 |
| Principal investigator 1 | Epizyme, Inc. | $1,847.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281240 |
| Principal investigator 1 | Genentech, Inc. | $3,889.00 | 05/28/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676672 |
| Principal investigator 1 | Genentech, Inc. | $49,853.00 | 05/14/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676749 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,016.00 | 05/07/2025 | Non-covered Recipient Entity BAYLOR RESEARCH INST | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185555746 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665202 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665216 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665224 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,079.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665248 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665254 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665256 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665368 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,982.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665370 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665394 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,982.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665422 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665450 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,079.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665462 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,457.30 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665464 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665484 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 05/05/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665492 |
| Principal investigator 1 | Epizyme, Inc. | $27.00 | 05/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281200 |
| Principal investigator 1 | ABBVIE INC. | $6,537.70 | 04/30/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202480509 |
| Principal investigator 1 | Epizyme, Inc. | $41.00 | 04/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281036 |
| Principal investigator 1 | BeiGene, Ltd. | $1,514.00 | 04/17/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190323126 |
| Principal investigator 1 | Celgene Corporation | $2,500.00 | 04/16/2025 | Non-covered Recipient Entity Texas Onco Southwest Fort Worth | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. | No dispute reported | 06/30/2026 | 1222304637 |
| Principal investigator 1 | Genentech, Inc. | $10,971.00 | 04/16/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676762 |
| Principal investigator 1 | Genentech, Inc. | $379.00 | 04/08/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676754 |
| Principal investigator 1 | ABBVIE INC. | $4,525.91 | 04/03/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202469735 |
| Principal investigator 1 | Acerta Pharma LLC | $12,513.00 | 03/26/2025 | Non-covered Recipient Entity BAYLOR RESEARCH INST | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185555750 |
| Principal investigator 1 | Epizyme, Inc. | $2,674.00 | 03/24/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184280836 |
| Principal investigator 1 | Genentech, Inc. | $379.00 | 03/20/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676783 |
| Principal investigator 1 | Epizyme, Inc. | $4,991.00 | 03/19/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184280838 |
| Principal investigator 1 | BeiGene, Ltd. | $1,804.00 | 03/18/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190323124 |
| Principal investigator 1 | ABBVIE INC. | $1,517.10 | 03/13/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202463665 |
| Principal investigator 1 | ABBVIE INC. | $6,220.40 | 03/07/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202461948 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 03/06/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665180 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 03/06/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665184 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 03/06/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665198 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 03/06/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665338 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,515.50 | 03/06/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665446 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,539.00 | 03/06/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665452 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,359.00 | 03/06/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665474 |
| Principal investigator 1 | BeiGene, Ltd. | $4,319.43 | 03/04/2025 | Non-covered Recipient Entity Baylor Research Institute | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322012 |
| Principal investigator 1 | ABBVIE INC. | $1,517.10 | 02/27/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202454460 |
| Principal investigator 1 | ABBVIE INC. | $4,353.70 | 02/27/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202454464 |
| Principal investigator 1 | ABBVIE INC. | $4,353.70 | 02/25/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202453831 |
| Principal investigator 1 | BeiGene, Ltd. | $10,555.00 | 02/25/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190323122 |
| Principal investigator 1 | Epizyme, Inc. | $1,485.00 | 02/19/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184280822 |
| Principal investigator 1 | Epizyme, Inc. | $2,446.00 | 02/19/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184280824 |
| Principal investigator 1 | Epizyme, Inc. | $1,847.00 | 02/19/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184280826 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 02/19/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676688 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $35,252.93 | 02/12/2025 | Non-covered Recipient Entity Baylor Research Institute | A Phase III, Open-Label, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy followed by Rituximab in Subjects with Previously Untreated Follicular Lymphoma | No dispute reported | 06/30/2026 | 1235998736 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,276.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665146 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665148 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $813.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665152 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,982.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665162 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665168 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,105.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665170 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,539.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665182 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $65.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665196 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,457.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665200 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,105.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665210 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,825.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665212 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665218 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,457.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665220 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $455.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665234 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,539.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665242 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,457.30 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665250 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665252 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,105.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665258 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,457.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665266 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,079.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665268 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,825.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665276 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665284 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665288 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,525.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665296 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,825.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665302 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,275.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665308 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,982.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665316 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665320 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665326 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,105.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665334 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665340 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,105.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665344 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665348 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,825.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665358 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,105.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665364 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,275.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665372 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,457.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665378 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $548.60 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665382 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $548.60 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665384 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,457.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665386 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,457.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665396 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,825.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665402 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,539.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665406 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665408 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665412 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,539.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665418 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,525.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665420 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,525.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665424 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,825.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665426 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,359.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665434 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,457.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665436 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,275.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665440 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,525.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665442 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,525.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665444 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,457.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665448 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $548.60 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665454 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,275.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665456 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,515.50 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665460 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,275.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665466 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665468 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,276.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665476 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,515.50 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665478 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,275.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665486 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665488 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,426.00 | 02/12/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665490 |
| Principal investigator 1 | Eli Lilly and Company | $520.21 | 02/10/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187892694 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,950.00 | 02/07/2025 | Non-covered Recipient Entity Baylor Rsrch Inst Irb | A Study of Daratumumab | No dispute reported | 06/30/2026 | 1175278866 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 02/07/2025 | Non-covered Recipient Entity Baylor Rsrch Inst Irb | A Study of Daratumumab | No dispute reported | 06/30/2026 | 1175279899 |
| Principal investigator 1 | ABBVIE INC. | $9,484.76 | 02/06/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202448554 |
| Principal investigator 1 | Acerta Pharma LLC | $108.00 | 02/05/2025 | Non-covered Recipient Entity BAYLOR RESEARCH INST | A Phase 1b Multicenter Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185555754 |
| Principal investigator 1 | Genentech, Inc. | $31,416.00 | 01/28/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676692 |
| Principal investigator 1 | Genentech, Inc. | $38,864.00 | 01/28/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211676723 |
| Recipient | Novartis Pharmaceuticals Corporation | $486.14 | 01/28/2025 | Covered Recipient Physician | CABL001AUS08 | No dispute reported | 06/30/2026 | 1190293182 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,079.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665158 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $190.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665164 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665166 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $65.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665178 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $190.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665192 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665204 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $96.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665230 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665232 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665240 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $65.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665246 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $190.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665272 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $96.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665312 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,079.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665318 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665322 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,359.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665324 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,079.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665342 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,283.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665356 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665404 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $65.00 | 01/20/2025 | Non-covered Recipient Entity Texas Oncology, P.A - Research Department | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246665470 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 01/10/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY-BAYLOR SAMMONS CANCER CENTER | A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1240599847 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 01/10/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY-BAYLOR SAMMONS CANCER CENTER | A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1240599850 |
| Principal investigator 1 | Incyte Corporation | $10,250.00 | 01/10/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY-BAYLOR SAMMONS CANCER CENTER | A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1240599854 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 01/10/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY-BAYLOR SAMMONS CANCER CENTER | A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1240599856 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $201,019.12 | 01/09/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER | A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | No dispute reported | 06/30/2026 | 1190311957 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,728.15 | 01/09/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER | A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment | No dispute reported | 06/30/2026 | 1190311961 |
| Principal investigator 1 | Epizyme, Inc. | $1,005.00 | 01/08/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184280792 |
| Principal investigator 1 | Epizyme, Inc. | $3,613.00 | 01/08/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184280794 |
| Principal investigator 1 | Epizyme, Inc. | $1,720.00 | 01/08/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184280800 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,900.00 | 01/03/2025 | Non-covered Recipient Entity Baylor Rsrch Inst Irb | A Study of Daratumumab | No dispute reported | 06/30/2026 | 1175280908 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $111,692.98 | 01/01/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190311951 |